Yuko Takano

8PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 15, 2026
Comprehensive genomic profiling and tumor mutational burden in parathyroid carcinoma: a nationwide real-world study from Japan.

|Mar 08, 2026
FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito

|Nov 06, 2025
Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers.

Jing Li, Ravi Velaga, Yuko Takano

|Jun 23, 2025
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.

Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki

|May 20, 2025
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki

|May 02, 2025
Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.

Yuko Takano, Kazuyuki Mizuno, Madoka Iwase

Pageof 2

Frequent Collaborators

3 joint publications

Norikazu Masuda

2 joint publications

Tetsuhiro Yoshinami

2 joint publications

Nobuhiro Shibata

2 joint publications

Nobuyuki Tsunoda